1 week Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a BetZacks
The mean of analysts’ price targets for Monte Rosa Therapeutics (GLUE) points to a 100.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
X